Home › Therapeutic areas › Neurology › Myasthenia Gravis
Myasthenia Gravis (7 companies)
Companies with an active program in Myasthenia Gravis.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| CABA | Cabaletta Bio | DermatologyImmunology+2 Rare | 1 | Phase 2 | $280M | 8 |
| RNAC | Cartesian Therapeutics | ImmunologyNeurology+1 Rare | 1 | Phase 3 | $230M | 4 |
| IMVT | Immunovant | ImmunologyNeurology Rare | 1 | Phase 3 | $6.31B | 5 |
| KYTX | Kyverna Therapeutics | ImmunologyNeurology+1 Rare | 1 | NDA Submitted | $302M | 7 |
| NKTX | Nkarta | ImmunologyNeurology+1 Rare | 1 | Phase 1 | $124M | 8 |
| TGTX | Tg Therapeutics | Neurology Rare | 2 | Approved | $9.16B | 6 |
| VOR | Vor Biopharma | ImmunologyNeurology Rare | 1 | Phase 3 | $1.22B | 2 |
No companies match.